Susan E Waisbren1,2, Sanjay P Prabhu3, Patricia Greenstein4,5, Carter Petty3, Donald Schomer4,5, Vera Anastasoaie3, Kalin Charette3, Daniel Rodriguez6, Sai Merugumala6, Alexander P Lin4,6. 1. Boston Children's Hospital, 1 Autumn Street, #525, Boston, MA, 02115, USA. Susan.waisbren@childrens.harvard.edu. 2. Harvard Medical School, Boston, MA, USA. Susan.waisbren@childrens.harvard.edu. 3. Boston Children's Hospital, 1 Autumn Street, #525, Boston, MA, 02115, USA. 4. Harvard Medical School, Boston, MA, USA. 5. Beth Israel Deaconess Medical Center, Boston, MA, USA. 6. Brigham and Women's Hospital, Boston, MA, USA.
Abstract
INTRODUCTION: Researchers hypothesized that in phenylketonuria (PKU) high brain phenylalanine (Phe) levels and low brain tyrosine (Tyr) levels affect neuropsychological functioning. However, traditional magnetic resonance spectroscopy (MRS) yielded uncertain results of brain Phe and could not adequately measure brain Tyr. This pilot study examined the potential of correlated spectroscopy (COSY) to quantify these biomarkers and explain variability in neuropsychological functioning. METHODS: Nine adults with early treated classic PKU received magnetic resonance imaging (MRI) with COSY and a battery of neuropsychological tests. Brain Phe and Tyr in parietal white matter (PWM) were compared to results in gray matter of the posterior cingulate gyrus (PCG). RESULTS: Brain Phe ranged from 101 to 182 (mean = 136.76 ± 23.77) μmol/L in PCG and 76 to 185 (mean = 130.11 ± 37.88) μmol/L in PWM. Brain Tyr ranged from 4.0 to 7.4 (mean = 5.44 ± 1.01) μmol/L in PCG and 4.1 to 8.4 (mean = 5.90 ± 1.48) μmol/L in PWM. Correlation coefficients were largest for brain Phe PWM and measures of auditory memory (rho = -0.79), anxiety (rho = 0.79), and executive functioning (rho = 0.69). Associations were in the expected direction, with higher brain Phe and lower brain Tyr related to poorer functioning. The two participants with severe structural MRI abnormalities had low brain Tyr levels in PCG and 3/5 of the participants with moderate to severe MRI abnormalities had higher than average brain Phe levels. CONCLUSION: COSY has the potential to quantify brain Phe and Tyr at low concentrations and in specific brain regions. In this pilot study, these biomarkers were associated with indices of neuropsychological functioning. Additional studies are needed to validate the COSY results.
INTRODUCTION: Researchers hypothesized that in phenylketonuria (PKU) high brain phenylalanine (Phe) levels and low brain tyrosine (Tyr) levels affect neuropsychological functioning. However, traditional magnetic resonance spectroscopy (MRS) yielded uncertain results of brain Phe and could not adequately measure brain Tyr. This pilot study examined the potential of correlated spectroscopy (COSY) to quantify these biomarkers and explain variability in neuropsychological functioning. METHODS: Nine adults with early treated classic PKU received magnetic resonance imaging (MRI) with COSY and a battery of neuropsychological tests. Brain Phe and Tyr in parietal white matter (PWM) were compared to results in gray matter of the posterior cingulate gyrus (PCG). RESULTS: Brain Phe ranged from 101 to 182 (mean = 136.76 ± 23.77) μmol/L in PCG and 76 to 185 (mean = 130.11 ± 37.88) μmol/L in PWM. Brain Tyr ranged from 4.0 to 7.4 (mean = 5.44 ± 1.01) μmol/L in PCG and 4.1 to 8.4 (mean = 5.90 ± 1.48) μmol/L in PWM. Correlation coefficients were largest for brain Phe PWM and measures of auditory memory (rho = -0.79), anxiety (rho = 0.79), and executive functioning (rho = 0.69). Associations were in the expected direction, with higher brain Phe and lower brain Tyr related to poorer functioning. The two participants with severe structural MRI abnormalities had low brain Tyr levels in PCG and 3/5 of the participants with moderate to severe MRI abnormalities had higher than average brain Phe levels. CONCLUSION: COSY has the potential to quantify brain Phe and Tyr at low concentrations and in specific brain regions. In this pilot study, these biomarkers were associated with indices of neuropsychological functioning. Additional studies are needed to validate the COSY results.
Authors: M A Thomas; K Yue; N Binesh; P Davanzo; A Kumar; B Siegel; M Frye; J Curran; R Lufkin; P Martin; B Guze Journal: Magn Reson Med Date: 2001-07 Impact factor: 4.668
Authors: Saadallah Ramadan; Ovidiu C Andronesi; Peter Stanwell; Alexander P Lin; A Gregory Sorensen; Carolyn E Mountford Journal: Radiology Date: 2011-02-25 Impact factor: 11.105
Authors: J Weglage; D Wiedermann; J Denecke; R Feldmann; H G Koch; K Ullrich; E Harms; H E Möller Journal: Ann Neurol Date: 2001-10 Impact factor: 10.422
Authors: Susan E Waisbren; Kay Noel; Kyle Fahrbach; Catherine Cella; Diana Frame; Alex Dorenbaum; Harvey Levy Journal: Mol Genet Metab Date: 2007-06-25 Impact factor: 4.797
Authors: J Weglage; D Wiedermann; J Denecke; R Feldmann; H G Koch; K Ullrich; H E Möller Journal: J Inherit Metab Dis Date: 2002-10 Impact factor: 4.982
Authors: Alexander P Lin; Saadallah Ramadan; Robert A Stern; Hayden C Box; Christopher J Nowinski; Brian D Ross; Carolyn E Mountford Journal: Alzheimers Res Ther Date: 2015-03-15 Impact factor: 6.982
Authors: Rachna Manek; Yao V Zhang; Patricia Berthelette; Mahmud Hossain; Cathleen S Cornell; Joseph Gans; Gulbenk Anarat-Cappillino; Sarah Geller; Robert Jackson; Dan Yu; Kuldeep Singh; Sue Ryan; Dinesh S Bangari; Ethan Y Xu; Sirkka R M Kyostio-Moore Journal: Sci Rep Date: 2021-11-24 Impact factor: 4.379